Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1948 1
1952 1
1953 1
1954 1
1955 1
1956 2
1958 2
1960 1
1961 1
1963 5
1964 9
1965 6
1966 9
1967 12
1968 17
1969 17
1970 11
1971 27
1972 9
1973 14
1974 23
1975 29
1976 17
1977 24
1978 28
1979 22
1980 21
1981 24
1982 33
1983 34
1984 27
1985 24
1986 28
1987 31
1988 32
1989 29
1990 33
1991 42
1992 37
1993 58
1994 64
1995 45
1996 46
1997 73
1998 70
1999 55
2000 60
2001 69
2002 57
2003 78
2004 69
2005 76
2006 92
2007 106
2008 128
2009 112
2010 132
2011 148
2012 156
2013 159
2014 173
2015 181
2016 187
2017 199
2018 216
2019 233
2020 258
2021 238
2022 230
2023 229
2024 88

Text availability

Article attribute

Article type

Publication date

Search Results

4,260 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Atrophic muscular disease"
Page 1
Neonatal hypotonia and neuromuscular conditions.
Mercuri E, Pera MC, Brogna C. Mercuri E, et al. Handb Clin Neurol. 2019;162:435-448. doi: 10.1016/B978-0-444-64029-1.00021-7. Handb Clin Neurol. 2019. PMID: 31324324 Review.
The differential diagnosis of neonatal hypotonia is a complex task, as in newborns hypotonia can be the presenting sign of different underlying causes, including peripheral and central nervous system involvement and genetic and metabolic diseases. This chapter describes ho …
The differential diagnosis of neonatal hypotonia is a complex task, as in newborns hypotonia can be the presenting sign of different underly …
Intensive care unit-acquired weakness: unanswered questions and targets for future research.
Piva S, Fagoni N, Latronico N. Piva S, et al. F1000Res. 2019 Apr 17;8:F1000 Faculty Rev-508. doi: 10.12688/f1000research.17376.1. eCollection 2019. F1000Res. 2019. PMID: 31069055 Free PMC article. Review.
We discuss critical aspects of ICU-AW that have not been completely defined or that are still under discussion. Critical illness polyneuropathy, myopathy, and muscle atrophy contribute in various proportions to ICU-AW. Diagnosis of ICU-AW is clinical and is based on Medica …
We discuss critical aspects of ICU-AW that have not been completely defined or that are still under discussion. Critical illness polyneuropa …
The Sick and the Weak: Neuropathies/Myopathies in the Critically Ill.
Friedrich O, Reid MB, Van den Berghe G, Vanhorebeek I, Hermans G, Rich MM, Larsson L. Friedrich O, et al. Physiol Rev. 2015 Jul;95(3):1025-109. doi: 10.1152/physrev.00028.2014. Physiol Rev. 2015. PMID: 26133937 Free PMC article. Review.
Some ICUAW forms require stringent diagnostic features; CIM is marked by membrane hypoexcitability, severe atrophy, preferential myosin loss, ultrastructural alterations, and inadequate autophagy activation while myopathies in pure sepsis do not reproduce marked myosin los …
Some ICUAW forms require stringent diagnostic features; CIM is marked by membrane hypoexcitability, severe atrophy, preferential myos …
Complexity of skeletal muscle degeneration: multi-systems pathophysiology and organ crosstalk in dystrophinopathy.
Ohlendieck K, Swandulla D. Ohlendieck K, et al. Pflugers Arch. 2021 Dec;473(12):1813-1839. doi: 10.1007/s00424-021-02623-1. Epub 2021 Sep 22. Pflugers Arch. 2021. PMID: 34553265 Free PMC article. Review.
Based on the establishment of comprehensive biomarker signatures of X-linked muscular dystrophy using large-scale screening of both patient specimens and genetic animal models, this article also discusses the potential usefulness of novel disease markers for more in …
Based on the establishment of comprehensive biomarker signatures of X-linked muscular dystrophy using large-scale screening of both p …
Assessment of Muscle Function and Physical Performance in Daily Clinical Practice : A position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).
Beaudart C, Rolland Y, Cruz-Jentoft AJ, Bauer JM, Sieber C, Cooper C, Al-Daghri N, Araujo de Carvalho I, Bautmans I, Bernabei R, Bruyère O, Cesari M, Cherubini A, Dawson-Hughes B, Kanis JA, Kaufman JM, Landi F, Maggi S, McCloskey E, Petermans J, Rodriguez Mañas L, Reginster JY, Roller-Wirnsberger R, Schaap LA, Uebelhart D, Rizzoli R, Fielding RA. Beaudart C, et al. Calcif Tissue Int. 2019 Jul;105(1):1-14. doi: 10.1007/s00223-019-00545-w. Epub 2019 Apr 10. Calcif Tissue Int. 2019. PMID: 30972475 Free article. Review.
MYTHO is a novel regulator of skeletal muscle autophagy and integrity.
Leduc-Gaudet JP, Franco-Romero A, Cefis M, Moamer A, Broering FE, Milan G, Sartori R, Chaffer TJ, Dulac M, Marcangeli V, Mayaki D, Huck L, Shams A, Morais JA, Duchesne E, Lochmuller H, Sandri M, Hussain SNA, Gouspillou G. Leduc-Gaudet JP, et al. Nat Commun. 2023 Mar 2;14(1):1199. doi: 10.1038/s41467-023-36817-1. Nat Commun. 2023. PMID: 36864049 Free PMC article.
Mytho is significantly up-regulated in various mouse models of skeletal muscle atrophy. Short term depletion of MYTHO in mice attenuates muscle atrophy caused by fasting, denervation, cancer cachexia and sepsis. While MYTHO overexpression is sufficient to trigger mu …
Mytho is significantly up-regulated in various mouse models of skeletal muscle atrophy. Short term depletion of MYTHO in mice attenua …
Update on muscle disease.
Witherick J, Brady S. Witherick J, et al. J Neurol. 2018 Jul;265(7):1717-1725. doi: 10.1007/s00415-018-8856-1. Epub 2018 Apr 18. J Neurol. 2018. PMID: 29671051 Review.
In this article, we highlight some of the most important developments from the last few years in the field of muscle diseases, including new additions to the congenital myasthenic syndromes (CMS) and limb-girdle muscular dystrophies (LGMD), advances in our understan …
In this article, we highlight some of the most important developments from the last few years in the field of muscle diseases, includ …
Motor neuropathy.
Andersen H. Andersen H. Handb Clin Neurol. 2014;126:81-95. doi: 10.1016/B978-0-444-53480-4.00007-2. Handb Clin Neurol. 2014. PMID: 25410216 Review.
Studies using MRI have shown that muscle weakness is paralleled by muscular atrophy within the feet and lower legs and in follow-up studies this atrophy is accelerated compared to healthy controls and non-neuropathic patients. ...
Studies using MRI have shown that muscle weakness is paralleled by muscular atrophy within the feet and lower legs and in foll …
Muscle Atrophy: Present and Future.
Cao RY, Li J, Dai Q, Li Q, Yang J. Cao RY, et al. Adv Exp Med Biol. 2018;1088:605-624. doi: 10.1007/978-981-13-1435-3_29. Adv Exp Med Biol. 2018. PMID: 30390273 Review.
Muscle atrophy is the loss of muscle mass and strength, and it occurs in many diseases, such as cancer, AIDS (acquired immunodeficiency syndrome), congestive heart failure, COPD (chronic obstructive pulmonary disease), renal failure, and severe burns. ...Here …
Muscle atrophy is the loss of muscle mass and strength, and it occurs in many diseases, such as cancer, AIDS (acquired immunod …
Anoctamin-5 related muscle disease: clinical and genetic findings in a large European cohort.
de Bruyn A, Montagnese F, Holm-Yildiz S, Scharff Poulsen N, Stojkovic T, Behin A, Palmio J, Jokela M, De Bleecker JL, de Visser M, van der Kooi AJ, Ten Dam L, Domínguez González C, Maggi L, Gallone A, Kostera-Pruszczyk A, Macias A, Łusakowska A, Nedkova V, Olive M, Álvarez-Velasco R, Wanschitz J, Paradas C, Mavillard F, Querin G, Fernández-Eulate G, Quinlivan R, Walter MC, Depuydt CE, Udd B, Vissing J, Schoser B, Claeys KG. de Bruyn A, et al. Brain. 2023 Sep 1;146(9):3800-3815. doi: 10.1093/brain/awad088. Brain. 2023. PMID: 36913258
Anoctamin-5 related muscle disease is caused by biallelic pathogenic variants in the anoctamin-5 gene (ANO5) and shows variable clinical phenotypes: limb-girdle muscular dystrophy type 12 (LGMD-R12), distal muscular dystrophy type 3 (MMD3), pseudometabolic my …
Anoctamin-5 related muscle disease is caused by biallelic pathogenic variants in the anoctamin-5 gene (ANO5) and shows variable clini …
4,260 results